Document Detail


The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression - an MR spectroscopy study.
MedLine Citation:
PMID:  18533184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rapid improvement of depressive symptoms occurs after the administration of the NMDA antagonist ketamine. Ketamine administration is accompanied by an increase in GLX (sum-peak of glutamate, glutamine (GLN) and GABA) and GLN in the brain, as measured by magnetic-resonance (MR) spectroscopy. In healthy subjects, we observed an increase in GLX and GLN levels after total sleep deprivation (TSD), which has a rapid antidepressant effects. We examined, if an increase in GLX or GLN is related to the therapeutic effect of TSD. We examined 13 patients with major depression by means of proton MR spectroscopy (field strength: 1.5T) before and after 24h of TSD. Two anatomical areas (dorsolateral prefrontal cortex (DLPC) and parieto-occipital cortex (POC)) were studied. In the DLPC TSD did not change GLX or its elements, whereas the total creatine and choline signal increased marginally. No change could be observed in the POC. For further exploration we took gender and the presence of vegetative characteristics of melancholic depression into account, i.e. the presence of early morning awakening, appetite and weight loss was taken into account, to define vegetative melancholia (VM). TSD led to an increase in GLX and GLN in the DLPC only of male patients. In patients with VM an increase in GLN occurred in this area. The low field strength limits the accuracy for GLX and GLN estimates. Despite the exploratory nature of the study, it nevertheless supports earlier data on the importance of glutamatergic neurotransmission and furthermore of gender and/or vegetative features in depression.
Authors:
Harald Murck; Mirjam I Schubert; Dagmar Schmid; Petra Schüssler; Axel Steiger; Dorothee P Auer
Related Documents :
22759944 - Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizop...
19382284 - 31phosphorus magnetic resonance spectroscopy study of tissue specific changes in high e...
19995444 - Psychological benefits 2 and 4 weeks after a single treatment with near infrared light ...
9189144 - Discriminative use of spect in frontal lobe-type dementia versus (senile) dementia of t...
17520464 - Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and sca...
23981404 - Treating generalized anxiety disorder using complementary and alternative medicine.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2008-06-03
Journal Detail:
Title:  Journal of psychiatric research     Volume:  43     ISSN:  0022-3956     ISO Abbreviation:  J Psychiatr Res     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-29     Completed Date:  2009-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376331     Medline TA:  J Psychiatr Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-80     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Max-Planck-Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. harald.murck@novartis.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Analysis of Variance
Antidepressive Agents / administration & dosage,  therapeutic use*
Choline / metabolism
Creatine / metabolism
Depressive Disorder, Major / drug therapy*,  metabolism,  psychology
Female
Glutamic Acid / metabolism*
Glutamine / metabolism*
Humans
Image Interpretation, Computer-Assisted
Magnetic Resonance Spectroscopy / methods
Male
Middle Aged
Occipital Lobe / drug effects,  metabolism
Parietal Lobe / drug effects,  metabolism
Prefrontal Cortex / drug effects,  metabolism
Psychiatric Status Rating Scales
Sex Factors
Sleep Deprivation / physiopathology*
Treatment Outcome
gamma-Aminobutyric Acid / metabolism
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 56-12-2/gamma-Aminobutyric Acid; 56-85-9/Glutamine; 56-86-0/Glutamic Acid; 57-00-1/Creatine; 62-49-7/Choline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challen...
Next Document:  Activated protein C attenuates intestinal mucosal injury after mesenteric ischemia/reperfusion.